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Abstract
The following review examines the role of calcium in promoting the in vitro and in vivo activation
of transglutaminases in neurodegenerative disorders. Diseases such as Alzheimer's disease,
Parkinson's disease and Huntington's disease exhibit increased transglutaminase activity and rises in
intracellular calcium concentrations, which may be related. The aberrant activation of
transglutaminase by calcium is thought to give rise to a variety of pathological moieties in these
diseases, and the inhibition has been shown to have therapeutic benefit in animal and cellular models
of neurodegeneration. Given the potential clinical relevance of transglutaminase inhibitors, we have
also reviewed the recent development of such compounds.
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Transglutaminases (TGs) catalyze various modifications of glutaminyl (Q) residues including
covalent intra- and inter-molecular crosslinking with lysyl (K) residues. The activity of these
enzymes and the products thereof are markedly increased in a variety of neurodegenerative
disorders. Moreover, proteins thought to be pathogenic in these diseases are often TG
substrates. Despite these findings, there is ambiguity concerning the role that TGs play in
disorders, such as Alzheimer's disease (AD), Parkinson's disease (PD) or Huntington's disease
(HD), and of the therapeutic benefit of inhibiting TG activity in these disorders. This ambiguity
is partly due to questions concerning the activation of these enzymes in vivo. Depending on
the TG, these enzymes are activated by a combination of proteolysis and Ca2+ or Ca2+ alone,
and inhibited by GTP. Although little is known regarding the levels of cerebral GTP in
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neurodegenerative disorders, increases in intracellular Ca2+ (Ca2+i) are recognized to be an
important, if not essential, factor in the etiology of neurological diseases. Given the propensity
of disease-specific increases in Ca2+i to stimulate in vivo TG activity, we have sought to review
the activation of TGs by this cation in both in vitro and neuropathological contexts to better
understand the involvement of these enzymes in pathologies such as AD, PD and HD. Since
TGs are likely to contribute to these diseases we have also reviewed recent developments in
the search for selective TG inhibitors.
Cerebral TGs & γ-glutamylamine formation
The brain expresses at least four of the eight active TGs produced by mammals, namely TGs
1−3 [1-3] and 6 [4]. TGs catalyze a variety of modifications of the carboxamide moiety [-C
(O)NH2] of Q residues, including transamidation [5], deamidation [6,7] and esterification [8],
in which the carboxamide moiety is modified to [-C(O)NHR], [-CO2−] and [-C(O)OR],
respectively. Even so, the only reaction attributed to cerebral TGs thus far is transamidation.
This reaction converts the carboxamide moiety of a Q residue to a substituted carboxamide
using amine-bearing compounds such as monoamines, diamines, polyamines and K residues
as attacking nucleophiles [5]. Of the possible reaction products, the γ-glutamyl-ε-lysine [Nε-
(γ-L-glutamyl)-L-lysine] isopeptide linkage formed between the Q and K residues, is the most
commonly studied. This bond can be formed both within and between polypeptide chains. The
placement of γ-glutamyl-ε-lysine linkages between polypeptides may result in protein
aggregation. Since the deposition of multimeric structures is a common feature of
neurodegenerative disorders, the formation of γ-glutamyl-ε-lysine bonds and the inhibition
thereof has attracted much interest. TGs can also crosslink polypeptides with bis-γ-
glutamylpolyamine bridges [9,10]. These bridges are formed by two successive
transamidations, the first of which involves the attack of a polyamine on a Q residue to generate
a γ-glutamylpolyamine residue. This moiety has a free terminal amine allowing it to participate
in a second transamidation and thereby produce a bis-γ-glutamylpolyamine linkage. γ-
Glutamylamines are excised unaltered during proteolysis and the amount of these freed
molecules reflects in situ TG activity [11-13]. Based on such measurements, bis-γ-
glutamylputrescine crosslinks appear to be formed at least as frequently as γ-glutamyl-ε-lysine
isopeptide linkages [11]. Of the free γ-glutamylamines thus far identified in human
cerebrospinal fluid (CSF; i.e., γ-glutamylspermidine, bis-γ-glutamylputrescine, γ-glutamyl-ε-
lysine and bis-γ-glutamylputrescine), γ-glutamylspermidine at a concentration of 670 nM, is
the most prevalent [11]. The concentration of bis-γ-glutamylputrescine in CSF exceeds that of
γ-glutamylputrescine by approximately sixfold (i.e., 242 vs 39 nM). If the concentration of
bis-γ-glutamylspermidine similarly exceeds that of γ-glutamylspermidine then bis-γ-
glutamylpolyamine bonds would represent the predominant crosslink formed by TGs in the
brain.
Recent studies suggest that some proteins crosslinked by γ-glutamyl-ε-lysine bridges may be
relatively soluble [14,15]. In one study, a thioredoxin fusion protein containing a Q65 domain
spontaneously formed noncovalent insoluble aggregates [14]. In the presence of TG 2, soluble
high-molecular-weight polymers were obtained. However, inhibition of γ-glutamyl-ε-lysine
crosslink formation by putrescine or by 5-biotin amidopentylamine antagonized the ability of
TG 2 to form soluble high-molecular-weight polymers [14]. The antagonism by putrescine is
presumed to be the result of covalent formation of γ-glutamylpolyamine linkages. These studies
suggest that endogenous polyamines may modulate the formation of TG-catalyzed soluble
aggregates. Despite these observations, little is known regarding the levels of either γ-
glutamylpolyamines or bis-γ-glutamylpolyamines in the brain and much less is known
regarding the proteins in which these crosslinked species are present.
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The ability to infer observations about in situ TG activity from the levels of free γ-
glutamylamines derives from a novel aspect of the TG reaction. γ-Glutamylamine bonds are
resistant to the action of proteases. Consequently, γ-glutamylamines are excised intact when
proteins containing these residues are degraded by proteolysis. The amide bond in free γ-
glutamylamines can be cleaved by γ-glutamylamine cyclotransferase to produce free amine
and 5-oxoproline. However, the activity of this enzyme in brain is low [16] and we have
suggested that levels of free γ-glutamylamines are a good surrogate for in vivo TG activity in
brain [11-13]. The resistance of the γ-glutamylpolyamine bonds to proteolysis suggests a novel
permanent alteration of proteins. Polyamination increases the activity of a number of enzymes
[17-19], notably phospholipase A2. In the case of phospholipase A2, the covalent attachment
of polyamines causes a threefold increase in specific activity [17]. If this change persists for
the life of this enzyme then it would represent a profound change in overall lipase activity.
This is in stark contrast to the transient nature of some other post-translation modifications that
affect enzymatic activity (e.g., phosphorylation), which typically last from seconds to minutes
depending on the substrates. Thus, polyamination has the potential to bring about global and
persistent changes in cellular metabolism. Such changes may herald crucial progressions in
disease etiology. For example, the polyamination of phospholipase A2 would significantly
increase the production of leukotrienes and prostaglandins and by this mechanism could
contribute to the inflammation associated with many neurodegenerative disorders.
Ca2+ & TG activation
Ca2+ is absolutely required for the activation of the well-studied TGs [20]. Moreover, the full
activation of these enzymes in most in vitro assays requires millimolar concentrations of
Ca2+. Mammalian blood and interstitial fluid contain millimolar amounts of Ca2+ capable of
activating extracellular TG 2 and factor XIII, and do so as indicated by the presence of γ-
glutamylamine linkages in extracellular matrices, cell envelopes and blood clots [21,22]. Blood
clots in the horseshoe crab also contain crosslinked proteins [23]. With the exception of those
in the outer epidermis, cells typically maintain basal concentrations of cytosolic Ca2+ between
20 and 100 nM and allow increases of up to 500 nM following cellular activation [24]. This
range of permittable Ca2+i concentrations raises the question of how the intracellular TGs are
activated. TGs are clearly activated within cells as evidenced by the presence of γ-
glutamylamine bonds in cellular proteins [10] and the demonstration of polyamination in cell-
based models [25,26]. The tertiary structures of TGs 1−3 have been resolved and indicate the
presence of three conserved Ca2+-binding sites on these enzymes [27-32]. Unfortunately, these
studies have not suggested a mechanism for the full activation of TGs at cytosolic Ca2+
concentrations. Nonetheless, the known locations of the three TG Ca2+-binding sites have
provided valuable insights into the catalysis of transamidation.
Despite limited sequence homology (e.g., TG 2 and 3 share 40% identity) [27,28], TGs conform
to a common architecture of four contiguous ellipsoidal domains: an N-terminal β sandwich
followed by a catalytic core, and then two C-terminal β barrels. A hinge region (Leu312–
Arg317 in TG 2) connects the catalytic core domain to the first β barrel and facilitates the
occupation of at least two conformational states: closed and open [32]. In the closed state, the
hinge region resembles a β strand and allows the β barrels to drape across the active site and
prevent substrate access (Figure 1). Enzyme activation causes the hinge region to conform to
an α helix, which in turn forces the domains into an open conformation exposing the active
site (Figure 2). This movement displaces the β barrels by as much as 120 Å and represents a
substantial conformational change. The demonstration of these conformational states has been
of particular importance, as it has revealed for the first time how two protein TG substrates
might interact simultaneously with the catalytic core [32].
Jeitner et al. Page 3













An interesting hypothesis to account for the conversion of the hinge region from a β strand to
an α helix invokes a prolyl cis–trans isomerization to power the change. Transition between
the cis and trans conformations require a 180° change in the orientation of the prolyl bond and
as such can produce profound effects in protein secondary structure [33,34]. TGs 1−3 contain
a cis prolyl bond in the hinge region (Gly472–Pro473 in TG 3) and, therefore, isomerization of
this bond may be sufficient to induce the hinge β-strand to assume an α-helical conformation
[28,31]. This type of mechanism has successfully accounted for the conformational changes
of other multidomain proteins [35]. Investigations of prolyl cis–trans isomerizations in proteins
usually require nuclear magnetic resonance (NMR)-based techniques [36]. However, the
structures of TGs 1−3 are too large to be resolved by current NMR methods. Other tests for
the involvement of prolyl isomerization could involve mutation of the Pro473 residue and NMR-
based conformational studies of the TG catalytic core domain bound only to the nearest β barrel
via the hinge region. Ahvazi and coworkers [31] have pointed out that prolyl isomerization
may occur at too slow a rate to account for the kinetics of TG-catalyzed reactions (the activation
energy of prolyl isomerization is ∼20 kcal/mol) [33]. Indeed, prolyl isomerization may account
for the lag period commonly observed in assays of TG kinetic activity. Prolyl isomerases
significantly increase the rate of isomerization [34] and may act in concert with TGs to catalyze
transamidation in vivo. This hypothesis could be readily tested by an investigation of the effect
of prolyl isomerases on the kinetics of TG reactions.
Cis peptide bonds are metastable and are kept in place by extensive hydrogen bonding and
hydrophobic side chain interactions. Disruption of these stabilizing forces favors prolyl cis–
trans isomerization. However, the TG Ca2+-binding sites are not sufficiently close to the hinge
cis prolyl bond to directly impinge on its chemical environment [30]. Nonetheless, Ca2+-
induced conformational alterations in the neighboring catalytic core may affect the cis–trans
isomerization of the Gly472–Pro473 peptide bond. Ca2+ binds at three highly conserved sites
within the catalytic core domain of TGs 1−3 [30,31,37]. Site 1 in TG 3 is defined by Ala221,
Asn224, Asn226 and Asp228 (Figure 3) and binds Ca2+ with an affinity of 0.3 μM. This tight
binding suggests that the Ca2+ at site 1 is essentially permanently bound to the enzyme and
acts to stabilize the local structure [30]. Ca2+ binds to sites 2 (Asn393, Ser415, Glu443 and
Glu448;Figure 4) and 3 (Asp301, Asp303, Asn305, Ser307 and Asp324;Figure 5) with a lower
average affinity of 3 μM and can dissociate from the enzyme. The binding of Ca2+ to sites 2
and 3 causes large conformational changes in TG [28,30]. Sites 2 and 3 are also in close
proximity to cis peptide bonds between Pro372–Tyr373 and Gly472–Lys488 and, therefore,
Ca2+ binding may induce the cis–trans isomerization of these bonds. Pro372–Tyr373 and
Gly472–Lys488 peptide bond isomerization may, in turn, alter the conformation of the hinge
Gly472–Pro473 peptide bond and displace the β barrels from the catalytic core.
The binding of two Ca2+ ions (given that one Ca2+ is permanently associated with site 1) to
the catalytic core domain induces TG 2 to adopt an open conformation exposing the substrate
binding sites and the catalytic residues [32]. Q-bearing substrates typically containing
sequences QxPϕD(P), QxPϕ or QxxϕDP (where ϕ represents hydrophobic amino acids) [38],
bind to a hydrophobic pocket consisting of Ala304, Leu 312, Ile313, Phe316, Ile 331 and Leu420
in the TG 2 catalytic core [32]. The conformational changes that allow substrate binding also
juxtapose Cys277 to Trp241, which then form a thiolate–imidazolium ion pair oriented by
Asp358. These changes allow a nucleophilic attack by the thiolate ion on the electron-deficient
carbonyl of the γ carboxyamine group to generate an oxyanion intermediate [39]. The charge
on the oxyanion is stabilized by hydrogen bonding with the backbone nitrogen of Cys277 and
Nε1 nitrogen of Try241. Subsequent acylation results in the release of NH3 and the formation
of an acyl-enzyme intermediate. The amine-bearing substrate then approaches the acylated
Cys277 via a tunnel roofed by Typ241 and Trp332 and guided by Try360 [32,39]. Nucleophilic
attack by the amine group leads to the formation of a second oxyanion, again stabilized by
hydrogen bonding with Cys277 and Try241. Deacylation then completes the reaction.
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The key residues and structural motifs cited above are conserved among TGs 1−3 and make it
likely that the aforementioned reaction scheme is shared by these enzymes. Thus, ‘dormant’
TG exists in a closed conformational state in which the β barrels obscure the catalytic core.
This self- or auto-inhibition is relieved by Ca2+ binding to two sites in the catalytic core, causing
the β-barrels to be displaced in such a manner as to expose the catalytic quartet of Asp358,
His335, Cys277 and Trp241 (in TG 2) and allow the binding of up to two protein substrates. The
substrate Q residue undergoes a nucleophilic attack by the activated thiolate of Cys277 to
generate an acyl intermediate, which in turn undergoes a nucleophilic attack by an amine-
bearing substrate. Subsequent deacylation releases the substrate bearing an amide-substituted
Q residue.
Equilibrium dialysis studies have established that Ca2+ binds TG 3 at micromolar
concentrations [28,30], so why are millimolar amounts of Ca2+ required to activate these
enzymes in vitro? This is an important question, since in the absence of an adequate explanation
it has been suggested that TGs are rarely activated in some in vivo situations. These suggestions
ignore both the presence of these enzymes within cells and the presence of γ-glutamyl linkages
in the body. The explanation probably resides with the choice of Q-bearing substrates chosen
for in vitro TG assays. Casein (or N,N-dimethylcasein) is commonly used to assay TG activity.
This protein is typically extracted in a phosphate buffer and consequently has a high content
of covalently bound phosphate [40]. As noted earlier, the binding site for Q-bearing substrates
in TG 1−3 is a hydrophobic pocket. The charge imparted by phosphate could interfere with
the binding of casein to TG. Ca2+ readily binds and neutralizes the charge on phosphate and
this neutralization may account for the millimolar Ca2+ requirement in TG assays. Indeed, the
Km of TG 2 for Ca2+ becomes 3−4 μM when dephosphorylated, rather than phosphorylated,
casein is used as substrate in in vitro assays [41]. These observations and those demonstrating
the formation of γ-glutamylamine linkages in situ indicate that TGs can be, and are, activated
by physiological levels of Ca2+i concentrations.
The activation of TG 2 by Ca2+ is attenuated by GTP [25,29]. TG 1 also contains a guanosine-
binding site but its ability to catalyze transamidation is not inhibited by GTP [31]. While
Ca2+ has little effect on the binding of GTP to TG 2, it does lower the rate of GTP hydrolysis
by this enzyme [31]. GTP induces conformational changes in TG 2, but how these changes
might affect Ca2+ binding to sites 1, 2 or 3 is unknown. Unfortunately, very little is known
regarding guanosine nucleotide concentrations in the brain, making it difficult to evaluate the
role of GTP binding and hydrolysis in the regulation of cerebral TGs.
Overview of Ca2+i homeostasis in the brain
An approximately 10,000-fold differential exists between the extra- (∼1−2 mM) and intra- (50
−100 nM) cellular pools of Ca2+. Since this gradient is so great the plasma membrane channel
responsible for Ca2+ entry into cells only allows small amounts of this ion to access the cytosol
at any time. This Ca2+ signal is subsequently amplified by Ca2+ release from the endoplasmic
reticulum (ER) via two channels: the inositoltrisphosphate (IP3)-responsive channel and the
ryanodine receptor (RyR). IP3 is often cleaved from phosphatidylinositol 4,5-bisphosphate
(PIP2) in conjunction with the opening of plasmalemmal Ca2+ channels. The release of Ca2+
from the ER via IP3-channels causes an increase in Ca2+i, which in turn, signals additional
Ca2+ release from the ER via the RyR. These elevations in Ca2+ concentrations are countered
by ATP-dependent Ca2+ pumps, which operate to either expel Ca2+ from the cell or to sequester
it within mitochondria or the ER. Schematically, these processes can be represented as:
Plasma membrane channels (+) → IP3-responsive channels (++) → RyR (++++) → ATP-
dependent Ca2+ pumps (−).
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The positive and negative signs (shown in parentheses) represent the net effect of these channels
and pumps on Ca2+i concentrations.
AD: features & hypotheses
The most common form of dementia affecting humans is AD, which manifests as progressive
memory loss and cognitive decline. In most cases, these manifestations of AD appear after 65
years of age and are a harbinger of death. AD primarily affects the pyramidal neurons of the
hippocampus and is distinguished by an excessive deposition of amyloid plaques and
neurofibrillary tangles in the cerebral cortex [42]. Plaques are external to neurons and are
comprised of insoluble aggregates of amyloid β (Aβ) and other proteins, whereas tangles are
intracellular aggregates of hyperphosphorylated tau and other cytoskeletal elements. When AD
was first described in 1906, a relatively small percentage of adults survived beyond 60 years
of age or more, and consequently, the incidence of this disease was thought to be sporadic.
With the marked increase in life expectancy over the last 100 years, AD has been revealed to
be a frequent cause of death among the elderly. The risk factors for AD include advanced age,
poor diet, diabetes, hypertension, head trauma and inheritance of the ε4 allele of the
apolipoprotein E [42]. Specific mutations in the genes for Aβ precursor protein (APP),
presenilin 1 or presenilin 2, result in a rare and early-onset form of the disease known as familial
AD [43].
Two leading hypotheses have been put forward to account for the development of AD. The
first of these – the amyloid hypothesis – posits that Aβ deposits initiate the disease [44]. This
hypothesis is supported by several observations. The APP gene resides on chromosome 21.
Consequently, trisomy 21 (Down syndrome) sufferers have three copies of this gene and
invariably develop AD by 40 years of age [45]. Moreover, inheritance of the apolipoprotein E
ε4 allele leads to an excessive accumulation of cerebral Aβ-containing plaques, the deposition
of which precedes the behavioral changes associated with this disease. However, a number of
observations concerning Aβ-containing plaques are not consistent with the amyloid hypothesis.
For example, plaque distribution is not coincident with the histological pattern of damage in
AD, and ridding the brain of plaques with antibodies does not resolve the disease in humans
[46]. Moreover, in a mouse model of AD there is no close correlation between neuronal loss
and plaque formation [47]. The other major hypothesis to account for the development of AD
– the tau hypothesis – contends that neurofibrillary tangles primarily cause this disease [48].
TG expression & activity in AD
Transglutaminase activity is significantly increased in the affected regions of AD brain [1,
49] and TG 1, TG 2 and γ-glutamyl-ε-lysine are present in pathological lesions in AD brain
[3,50]. An increase in the amount of γ-glutamyl-ε-lysine crosslinked proteins in insoluble
protein in AD brain was shown previously [1]. TG 1 and TG 2 protein expression is increased
in AD brain [1], which presumably accounts at least in part for the increased TG activity in
AD brain. Many studies have focused on the expression of TG 1 in skin, where the enzyme is
regulated via AP1 and Sp1-binding sites [51], but the factors regulating the expression of TG
1 in brain have not been identified. The TG 2 promoter contains an NF-κβ-binding site through
which glutamate and inflammatory mediators have been shown to act [52-56], and both
glutamate excitotoxicity and inflammation are thought to contribute to AD. An alternatively
spliced truncated variant of the TG 2 message, termed ‘short TG 2’, is also generated in brains
of AD patients [57]. Short TG 2 expression may be particularly important in the later stages
of AD. Truncated TG 2 lacks the ability to bind GTP and promotes apoptosis in vivo
independently of the transamidation reaction [58].
γ-Glutamyl-ε-lysine immunoreactivity co-localizes with Aβ in senile plaques in AD brain
[3]. For TG 2 to catalyze γ-glutamyl-ε-lysine crosslinks in these plaques, the enzyme would
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require release from neurons. However, to the best of our knowledge, the export of TGs from
neurons has not been demonstrated. Nevertheless, TG 2 is present in CSF and in a greater
amount in AD[59] and PD patients [60]. The most likely source for this activity is the brain.
However, it should be noted that the activity could result either from cellular export (as shown,
for example, for endothelial and epithelial cells of noncerebral origin [61-63]) or from cell
lysis. Siegel et al. [64] have reported that extracellular TG 2 is catalytically inactive, but is
transiently activated upon tissue injury. However, other studies suggest that TG exported to
the extracellular environment is a ctivated by Ca2+ [61-63].
Amyloid β [65-67] and Aβ bearing the Dutch mutation (Q22 → E22) [66] are in vitro substrates
of TG2. The resulting polymers resemble the aggregates seen in AD brain, and it has been
suggested that TGs contribute to AD by initiating Aβ oligomerization and aggregation at
physiological levels [67]. Adballa et al. [68,69] demonstrated that the formation of Aβ leads
to oxidation of tyrosine residues of neighboring Ang II receptors (AT2) causing these proteins
to dimerize. The dimerized proteins are then substrates for further oligomerization by TGs.
Ang II AT2 oligomers sequester the Gαq/11 G protein, inhibiting its activity, and cause a
phenotype reminiscent of AD. The notion that TG-catalyzed aggregation causes pathology by
removing critical proteins has been proposed earlier. For example, glyceraldehyde 3-phosphate
dehydrogenase, α-ketoglutarate dehydrogenase complex and histones [70-72] are in vitro TG
substrates whose loss or covalent modification might compromise normal cell functioning.
Crosslinking of ubiquitin, HSP27, parkin and α-synuclein by γ-glutamyl-ε-lysine bonds in
Alzheimer's neurofibrillary tangles has been detected in AD brain [73]. Crosslinking of tau
was not detected in these studies (however, see below).
Transglutaminases may play a significant role in the stabilization of neurofibrillary tangles.
γ-Glutamyl-ε-lysine bonds have been identified within tangles [2,3,50,65] and the proteins that
comprise these structures are in vitro TG 2 substrates. These proteins include tau [26,50,
74-79] and α-synuclein [65,80-82]. The actions of TG on α-synuclein will be discussed below.
Mature TG 1 is variably myristoylated and palmitoylated, which causes this enzyme to
associate with the plasma membrane [83]. The binding of this enzyme to membranes
profoundly affects its substrate preference, especially with respect to which Q and K residues
are modified. Moreover, when bound to membranes, TG 1 can catalyze the addition of
ceramides to Q residues [8], which may contribute to the incorporation of fatty materials into
tangles. The membrane-binding portion of TG 1 can be removed by proteolysis to generate a
cytosolic form of the enzyme [83]. TG 2 and deacylated TG 1 share many of the same substrates
[84,85] and, therefore, cytosolic TG 1 may act on a number of the a forementioned TG 2
substrates (e.g., AT2).
Increases in neuronal Ca2+i in AD
The extracellular milieu is sufficiently rich in Ca2+ (1−2 mM) to maximally stimulate
proteolytically-activated factor XIII and any active TG 2 exported from cells [61-63], and to
contribute to the stabilization of Aβ plaques. Under these circumstances the major limits to
activity are likely to be clearance via the cerebral circulation, incorporation into biological
matrices (noncovalent associations and covalent attachment where one TG molecule acts as a
substrate for another) and substrate availability. With respect to the last point, blood and
interstitial fluid are poor sources of polyamines and, consequently, extracellular TG 2 would
be expected to produce a greater number of γ-glutamyl-ε-lysine linkages than either bis-γ-
glutamylpolyamine or γ-glutamylpolyamine linkages an expectation that has been
substantiated by in vitro studies [10,21].
Intracellular TGs may be activated by etiological factors associated with sporadic AD.
Kuchibhotla et al. have demonstrated that the pathological deposition of Aβ-containing plaques
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resulted in a rise in Ca2+i from approximately 80 to approximately 500 nM in 20% of the
neurons in the vicinity of the plaques [24]. Similarly, Busche et al. reported an increased
frequency of spontaneous Ca2+ transients in approximately 20% of the neurons in neighboring
plaques [86]. Thus, Aβ plaques may facilitate the generation of tangles by TGs by elevating
Ca2+i concentrations. How plaques allow Ca2+ into neurons has not been established. Busche
et al. have argued that plaques may interfere with the glutamatergic inhibition of synaptic
activity [86], whereas Kuchibhotla et al. suggest that these structures form Ca2+-conducting
pores, modulate voltage-gated Ca2+ channels or generate an oxidative stress that releases
calcium from intracellular stores [24]. The observations of these two groups were made using
murine models of AD and the differences reported (i.e., increased Ca2+i vs spontaneous
Ca2+ transients) are most likely due to differences in methodologies and the genetic background
of the mice. Regardless of their differences, these studies demonstrate that elevations in
Ca2+i concentrations are an important and consistent feature of sporadic AD etiology.
Some of the mutations that underlie familial AD also increase the concentration of Ca2+i in the
affected neurons. The ER is the major reservoir of Ca2+ within cells, and its Ca2+ stores are
replenished by ATP-dependent Ca2+ pumps. However, passive Ca2+ efflux leak channels act
in opposition to these pumps to ensure that the ER does not become overfilled with Ca2+. One
consequence of overfilling the ER is an exaggerated efflux of Ca2+ in response to either IP3 or
RyR activation. Presenilins 1 and 2 encode for passive ER Ca2+ leak channels and mutations
of these molecules account for approximately 40% of familial AD cases [87]. A significant
number of these mutations ablate the leak activity of presenilins, causing both an overfilling
of Ca2+ by the ER and an excessive Ca2+ efflux from this organelle upon stimulation [88,89].
Stutzmann and colleagues have demonstrated that mice bearing one of these presenilin 1
mutations (i.e., presenilin 1 M146V) show a threefold greater increase of Ca2+i in response to
IP3 relative to control animals [90]. Stutzmann and coworkers subsequently demon strated that
this response was primarily due to the passage of Ca2+ through the RyR [91]. The number of
RyRs increases with age and is associated with a greater rise in IP3-evoked Ca2+i with age in
presenilin 1 M146V-knockin mice [91]. Together, these observations suggest that increases in
Ca2+i levels, capable of inducing intracellular TG activity, are a consistent feature in AD.
Increases in neuronal Ca2+i during aging
Aging is one of the major risk factors for AD and other neurodegenerative disorders. As in the
case of animal AD models, the activation of RyRs is also thought to contribute to the elevations
in Ca2+i, observed in the hippocampal neurons of aging rodents. These elevations are primarily
caused by the opening of voltage-dependent Ca2+ channels and contribute to a number of
electrophysiological phenomena, including the slowing of the after-hyperpolarization phase
of action potentials with age, as well as increases in Ca2+ spikes, currents and transients [92].
Application of the RyR antagonist ryanodine to hippocampal slices lessens the effects of age
on the after-hyperpolarization and synaptically activated Ca2+ transients. Based on this
observation, Thibault et al. hypothesized that Ca2+ efflux from the ER, as mediated by the
RyR, is an important component of the age-dependent increase in neuronal Ca2+i [92]. This
hypothesis is further supported by studies that suggest the L-type voltage-dependent Ca2+
channels are situated close enough to RyRs to activate this ER channel [93].
It is important to note that the pathology of the aging rodent brain may be different from that
of humans. Aging rodents do not normally succumb to either familial or sporadic AD. Indeed,
the transfection of three separate mutated genes is required to produce a facsimile of human
AD in mice replete with the behavioral manifestations [94]. Even so, fibroblasts isolated from
AD patients do exhibit some of the aspects of altered Ca2+ homeostasis seen in AD mice
[95]. However, the relevance of murine aging to AD remains to be established. It will also be
important to determine the role of apoptosis in murine and human aging. Apoptosis commonly
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occurs in rodent models of neuro degeneration. Since apoptosis is usually restricted to dividing
cells this is a remarkable observation (nondividing cells typically die by macroautophagy), and
suggests that apoptosis is either unique to rodents or diseases such as AD per se. If the latter
is true then strategies that limit apoptosis should have therapeutic benefit in human
neurodegenerative diseases.
HD: features & TG hypothesis
Huntington's disease is primarily a movement disorder resulting from the death of mediumsized
spiny neurons in the striatum, and patients exhibit varying degrees of mental decline as the
disease progresses. In addition to the affected sites, HD differs from most cases of AD in that
the disease is due to mutations in a single gene. Despite its rarity – a frequency of 0.007%
worldwide – the availability of pertinent animal models, and the notion that many fundamental
processes underlying neurodegeneration are similar regardless of initiating factors or site of
injury, has stimulated significant research interest into HD.
Huntingdon's disease is due to an expansion of CAG repeats in the huntingtin (htt) gene and
these mutations are inherited in an autosomal dominant manner. The CAG expansions encode
stretches of polyglutamines (poly Q) in the N terminus of the htt protein, and mutations giving
rise to 39 or more contiguous Q residues in this protein invariably precipitate the disease
[96]; the longer the repeat the earlier the onset of the disease and the greater its rate of
progression [97,98]. DNA replication tends to expand mutant CAG repeat sequences, and
consequently, the number of mutant poly Q residues in htt tends to increase with each
succeeding generation, particularly in the case of paternal transmission. This phenomenon of
‘anticipation’ results in successively earlier disease onsets.
As in the case of AD, polymeric aggregates are deposited in affected brain regions of HD
patients [99]. The aggregates include mutant htt, which has a marked propensity to self-
aggregate in vitro [100]. Green suggested that mutant htt might be an excellent substrate of
TGs and that TG activity toward mutant htt might contribute to the etiology of HD [101]. TGs
were hypothesized to promote the aggregation of mutant htt in a manner that correlated with
the poly Q length. This hypothesis is supported by in vitro studies showing that contiguous Q
residues in model peptides/proteins [102-105] and mutant htt itself [106] are excellent TG
substrates. Moreover, γ-glutamyl-ε-lysine linkages are present in htt-containing aggregates in
intact HD brain [107].
TG expression & activity in HD
The greater amount of protein-bound and free γ-glutamylamines in HD brains and CSF, as
compared with controls, attests to the increased activation of cerebral TGs in this disease
[11-13,107]. TG activity is also greater in postmortem samples of HD versus control brain
[104,108] and relates to elevations in the message and amounts of TG 2 proteins [106,108].
HD is accompanied by inflammation and mediators of this process, such as TNF-α, may serve
to increase the expression of TG 2. The TG 2 promoter contains an NF-κB- binding region and
TNF-α stimulates both the translocation and DNA binding of NF-κB, as well as the expression
of TG 2 in microglia and astrocytes [55,109]. As noted earlier, the activation of TG 2 (and
possibly other TGs) may promote inflammation through the sustained activity of polyaminated
phospholipase A2.
Increases in neuronal Ca2+i during HD
The activation of TGs may be an early and significant consequence of HD since mutant htt
promotes Ca2+i elevations capable of stimulating the activity of these enzymes. Wild-type
htt binds to IP3 receptors and facilitates the release of Ca2+ through this combination channel-
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receptor [110]. However, mutant htt preferentially enhances the release of Ca2+ via the IP3
receptor following glutamate-dependent hydrolysis of PIP2 [111]. Glutamate excitoxicity in
HD is thought to be promoted mainly via the NMDA receptor and the activity of this receptor
is markedly increased in mutant htt-expressing mice [112,113]. Dopamine acts synergistically
to increase glutamate-dependent Ca2+i, presumably through the protein kinase A-catalyzed
phosphorylation of NMDA and AMPA receptors and through the dopamine type 2 receptor-
mediated hydrolysis of PIP2 [114]. Together, these processes would be expected to
significantly increase Ca2+i, and this has been confirmed in numerous studies with mice bearing
disease-causing mutations in htt [115,116].
Mutant htt also appears to increase the sensitivity of the permeability transition pore to Ca2+,
leading to dissipation of the mitochondrial membrane potential, and consequently, to a
diminished capacity of this organelle to store Ca2+ [117-120]. How mutant htt causes the above
effects is not known, but may involve binding partners that attach to mutant poly Q sequences.
These binding partners may also regulate TG activity.
Polyglutamine-expanded htt, calmodulin & TG in HD
The Ca2+-binding protein calmodulin associates with poly Q-expanded htt and through this
association regulates TG activity. Calmodulin was initially shown to regulate TG activity in
platelets, chicken gizzard [121] and the human erythrocyte cytoskeleton [122]. It was
subsequently demonstrated that inhibiting calmodulin or disrupting the association of
calmodulin with poly Q-expanded htt with a peptide derived from calmodulin (amino acids 76
−127), reduces the ability of poly Q-expanded htt to act as a TG substrate [123-125]. In addition
to preventing the TG from utilizing poly Q-expanded htt as a substrate, expression of this
peptide reduced the cytotoxicity and Ca2+i increase associated with expression of mutant htt
[124,125]. These changes were selective, as neither total TG activity nor calmodulin-dependent
kinase II activities were inhibited by the calmodulin peptide. In addition, the association of
calmodulin with another calmodulin-dependent enzyme, calcineurin, was not disrupted by the
calmodulin peptide [125]. Expression of the calmodulin peptide fragment in the striatum of a
transgenic mouse model of HD lessened the weight loss and motor dysfunction typically seen
in these animals [MUMA N, UNPUBLISHED DATA].
Toxic mechanisms for TGs in HD
Mice with HD (R6/1 transgenic mice expressing exon 1 of human htt that contains a greatly
expanded polyglutamine domain [116 Q repeats]) with a TG 2−/− genotype live longer than
littermates expressing TG 2+/+ and the mutant htt fragment [126]. In the R6/1:TG2−/− mice,
the TG 2 knockout encompassed the whole body. Although one cannot rule out the possibility
that the increased life expectancy in the R6/1:TG 2−/− mice is due to some beneficial effect
related to ablation of whole body TG2, it seems likely that the beneficial effect is due to local
loss of brain TG 2. Thus, the percentage of abnormal brain cells in the various groups of mice
at 18 and 25 weeks was found to be in the order R61>R6/1:TG 2+/−>R6/1:TG 2−/− [126].
Moreover, the isopeptide levels in the detergent-insoluble fraction of brain at 25 weeks of age
was also of the order R61>R6/1:TG 2+/−>R6/1:TG 2−/− [126]. These gradation effects argue
for a local beneficial effect of TG 2 ablation. Interestingly, the number of intranuclear
inclusions was in the reverse order (i.e., R61<R6/1:TG 2+/−<R6/1:TG 2−/−), despite the fact
that the brains of the R6/1:TG 2−/− mice exhibited tenfold less γ-glutamyl-ε-lysine linkages
than their R6/1 littermates [126]. Presumably, the residual γ-glutamyl-ε-lysine bonds in the
brains of R6/1, TG 2−/− mice are due to brain TGs other than TG 2. The seemingly paradoxical
finding of increased aggregates in the brains of the R6/1:TG 2−/− mice compared with those
in brains of the R6/1 mice may be explained by the findings of Lai et al. alluded to above
[14]. Thus, in the absence of TG 2, the poly Q domains will noncovalently form insoluble
aggregates. In the presence of TG 2, γ-glutamyl-ε-lysine crosslinking will retard the formation
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of these insoluble noncovalent aggregates. However, TG 2-catalyzed polyamination will a
ntagonize this effect. At the present time it is not clear whether the soluble protein aggregates
containing htt, the insoluble aggregates, or both, are toxic [14]. However, if the soluble form
was more toxic this would explain the findings of Mastroberardino et al. [126] and might
suggest that the level of polyamine in the brain is crucial to the contribution of TGs to HD.
The levels of polyamines in the brain decrease with age [127]. Thus, the ability of the HD brain
to prevent formation of soluble aggregates may be lessened with age. However, this possibility
has not yet been investigated.
In addition to HD, there are a number of other CAG/polyglutamine expansion diseases in which
TGs are hypothesized to possibly contribute to the disease process. These diseases have been
previously reviewed [105,128,129].
Parkinson disease
Parkinson disease is the most common neurodegenerative disorder after AD. This disease
results from the selective loss of dopaminergic neurons in the substantia nigra pars compacta
(SNc). In most cases, what causes the loss of these neurons is unknown. PD presents as tremor,
bradykinesia, rigidity and postural instability. The affected brain regions contain
intracytoplasmic aggregates known as Lewy bodies consisting of dense eosinophilic cores
surrounded by pale halos [130]. These structures have also been identified in some cases of
AD [131]. The major constituent of Lewy bodies is a 140-amino acid protein known as α-
synuclein [132]. A fragment of α-synuclein (the nonamyloid component [NAC]) is also found
in the Lewy bodies of PD patients [133] and in the neuritic plaques of AD patients [134].
Several lines of evidence suggest a central role of aggregated α-synuclein in the etiology of
PD. α-Synuclein fibrils are neurotoxic when added to cultured cells [135,136], and the
expression of human α-synuclein in mice results in progressive accumulation of α-synuclein
inclusions and a concomitant loss of dopamine-containing neurons in the basal ganglia [137].
Finally, missense point mutations in α-synuclein are associated with an early-onset, inherited
form of PD [138,139].
TGs, Ca2+ & Parkinson's disease
As in the case of AD [59], greater amounts of TG 2 have been observed in the CSF of PD
patients compared with control CSF [60]. α-Synuclein spontaneously forms aggregates [140].
Interestingly, dopaminergic neurons of the PD SNc exhibit greater staining for TG 2 and γ-
glutamyl-ε-lysine than those of aged-matched controls [141]. Immunoprecipitation studies
using antibodies that recognize either α-synuclein or γ-glutamyl-ε-lysine have demonstrated
the presence of γ-glutamyl-ε-lysine crosslinked mono- and oligomeric α-synuclein in PD nigral
neurons [141]. The formation of intramolecular γ-glutamyl-ε-lysine crosslinks in α-synuclein
results in a monomeric and more compact form of this protein that is unable to polymerize into
α-synuclein fibrils [80,81]. Based on these observations, it has been suggested that TGs in
neurodegenerative diseases act, to some extent, to curb the formation of insoluble, toxic
oligomers of α-synuclein, htt and other disease-relevant proteins. Notwithstanding the appeal
of this idea, it has yet to be demonstrated that soluble α-synuclein monomers or htt oligomers
are innocuous. Indeed, the amount of intramolecularly crosslinked α-synuclein in nigral
dopaminergic neurons was found to correlate with the progression of PD [141]. γ-Glutamyl-
ε-lysine-mediated crosslinking has the potential to modify the ubiquitination of proteins since
ubiquitin is bound to lysine residue by a reaction remarkably similar to TG-catalyzed
transamidation. Thus, γ-glutamyl-ε-lysine crosslinked proteins may be inappropriately
ubiquitinated and congest proteasomes. Components of the ubiquitin proteasome system have
been identified in aggregates in two polyglutamine expansion diseases [142-144]. In toto, these
observations suggest that the TG substrate pools in the brain change during aging or as neuro
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degenerative diseases progress, and that these changes may lead to the production of neurotoxic
species. These changes range from decrements in substrate pools, as in the case of polyamines
in the aging brain [127], to post-translational modifications of the substrates including
proteolysis [65], and phosphorylation of α-synuclein [136]. TGs may also contribute to
formation of toxic aggregates by polymerizing with molecules, such α-synuclein and poly Q-
expanded htt, and TG 2 has been identified within the deposits of these proteins [107].
Unlike other excitable cells in the brain, SNc neurons fire autonomously at a frequency of 2
−4 Hz, very much like cardiac pacemaker cells [145], although in PD the neurons exhibit bursts
of cyclic firing rather than a continuous train of action potentials [146]. Similar to heart cells,
SNc neurons also use Ca2+ rather than Na+ to carry the current. Ca2+ enters SNc cells by way
of L-type currents, which open frequently to accommodate the pacemaker functions of these
cells. Glutamate-evoked opening of L-type channels causes Ca2+i peak increases of 100 μM
[147], which is more than enough to stimulate TG activity. Surmeier has suggested that the
mitochondria in diseased SNc neurons leak Ca2+ into the cytosol since these organelles are
often damaged in PD [145]. This suggestion is supported by the observation that the expression
of calbindin, which binds Ca2+, confers protection against mitochondrial toxins in cultured
pheochromacytoma 12 (PC12) cells [148]. Thus, under physiological and pathological
conditions, TGs are either continuously activated in SNc neurons or regulated in a different
manner than in other cells. The latter possibility is most likely; however, at present, little is
known regarding the regulation of TG in either SNc or PD.
Progressive supranuclear palsy
Progressive supranuclear palsy (PSP) is a parkinsonian-like movement disorder characterized
clinically by early postural instability, supranuclear vertical gaze palsy, and behavioral and
cognitive disturbances [149]. This disease is characterized by neuronal loss, gliosis,
neurofibrillary tangles, neuropil thread and tau immuno-reactive astrocytes.
Immunoprecipitated proteins containing γ-glutamyl-ε-lysine crosslinks from the affected brain
regions in PSP exhibit labeling for paired helical filaments tau, indicative of the actions of TG
in this disease [150]. Increased TG activity and increased expression of TG 1 and 2 at the
protein and mRNA level has also been demonstrated for the selectively vulnerable brain regions
in PSP [151]. Ca2+ homeostasis is thought to be perturbed during PSP and may act to activate
TGs in this disease [152].
Depression & TGs
Depression is a common symptom of HD and other neurodegenerative diseases such as AD.
Signaling via the serotonergic pathway is an important component of depression, and
depression is often successfully treated with drugs that act to modulate this signaling. TGs
appear to influence serotonergic signaling by binding serotonin to the Rac1 G protein as
indicated by coimmunoprecipitation of Rac 1 and serotonin [153,154]. Moreover, this binding
is blocked with two strategies that attenuate TG activity, namely, treatment of cells with either
small interfering RNA against TG 2 or cystamine. The identity of the TG-catalyzed bond(s)
between serotonin and Rac 1 has as yet not been determined and the significance of its
formation in neurodegenerative diseases awaits further research.
TG inhibitors
A major emphasis in this review has been the role of Ca2+ in activating TGs in
neurodegenerative diseases. Intracellular Ca2+ concentrations are increased in AD and HD, as
is TG activity. However, the mechanisms by which Ca2+ increases in these diseases varies
considerably and argues against the use of calcium-channel blockers as possible therapeutics.
By contrast, the activation of TGs in these diseases is a common and potentially damaging
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consequence of the rise in Ca2+i. Thus, TG inhibitors are theoretically good candidates as
therapeutics in neurodegenerative disorders.
Numerous small amine-bearing compounds, including polyamines, cysteamine, cystamine,
hydroxylamine, methylamine and histamine act as competitive inhibitors of transamidation
catalyzed by TGs [5,155,156]. A primary amine bound to an aliphatic unbranched carbon chain
of 4 or 5 saturated carbon atoms is a common characteristic of this class of inhibitors, although
shorter amines, such as hydroxylamine, methylamine and cysteamine are also active, as is
cystamine. These compounds act as alternative TG substrates, and thereby divert the activity
of TGs. Of this group of compounds, cystamine (H2NCH2CH2SSCH2CH2SH; which also has
the possibility of reacting directly with the cysteine at the active site by sulfide–disulfide
interchange) has been the most extensively studied as a potential therapeutic and has been
shown to be beneficial in animal models of HD [13,157,158] and a neurotoxin model of PD
[159]. However, cystamine elicits several changes that may contribute to neuronal survival,
making it difficult to assess the role of TG inhibition in cystamine-induced neuroprotection.
For example, administration of cystamine to mice raises the level of brain cysteine [160,161].
Both cystamine and cysteamine raise the level of brain-derived neurotropic factor [162] in
animal models of HD. The compounds also inhibit macroautophagy [163] and apoptosis
[164] in cell models. The inhibition of apoptosis in HD cell models by cystamine is thought to
be caused by inhibition of caspase 3 activity [164]. Moreover, cystamine extends the lifespan
to a similar extent in a mouse model of HD in which TG 2 is ablated (R6/2:TG2−/− mice) to
that observed in control mice (R6/2:TG2+/+ littermates), indicating that the compound may not
be directly working through inhibition of TG2 [165]. However, chronic administration of
cystamine to mice results in decreased total TG activity in the brain [13,157]. This decrease
may be due to an inhibition of the transcription of TGs by cystamine-derived cysteamine. In
support of this idea, cysteamine attenuates the DNA binding of two factors – activator protein
1 and NF-κB [166] – that bind to the TG 1 and TG 2 promoters [53,56,167].
Many TG inhibitors have been designed or discovered by screening of compound libraries.
Irreversible TG inhibitors include sulfonamides [168], iodoacetamide [169], alkyl isocyanates
[170], phenylthioureas [171,172], 3-halo-4,5-dihydroisoxazoles [173-175],
tyrosinamidomethyl dihydrohaloisoxazoles [176], sulfonium methyl ketones [177], 2-[(2-
oxoproyl)thio]imidazolium derivatives [178], and αβ-unsaturated amides, epoxides and 1,2,4,-
thiadiazoles built around the well known acyl substrate Cbz-L-Gln-Gly of guinea pig TG 2
[179-181]. Many compounds in this last category are irreversible inhibitors in the micromolar
or submicromolar range.
Comparison of the structures and activities of these compounds revealed the importance of the
length and the electronic nature of the side chains of the inhibitor analogues of Cbz-Gln-Gly
[180]. Keillor et al. suggest that x-ray crystallographic analysis of TG 2, with or without the
inhibitor bound at the active site, might prove useful in the design of a more potent second
generation of thiadiazole TG 2 inhibitors [179-181]. Recently, Stein and colleagues used a
high-throughput procedure to screen a library of 110,000 drug-like molecules to search for
inhibitors of TG 2 [182,183]. The acyl donor and acyl acceptor substrates used were N,N-
dimethylcasein and N-boc-lys-NH-CH2-CH2-NH-dansyl, respectively. The screen produced
104 candidates including competitive, mixed-site and GTP-binding site inhibitors [182,183].
Particularly effective inhibitors were thieno[2,3-d]pyrimidin-4-one acylhydrazide and
derivatives [184]. Lai et al. have also used a high-throughput screening procedure to screen
for inhibitors of human TG 2 [185]. The authors identified several inhibitors, the most potent
of which were ZM39923, a Janus kinase inhibitor, and its metabolite ZM49829, with IC50
values of 10 nM and 5 nM, respectively. Tyrphostin and vitamin K3 were found to have
IC50 values in the micromolar range. The agents appeared to act in part by interfering with the
reduction of the vicinal disulfide needed for activation of TG. Interestingly, several of the
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agents uncovered by the screening were able to improve survival times in a Drosophila
melanogaster model of a polyglutamine expansion disease (Machado-Joseph disease) [185].
A number of groups have investigated the potential of peptide-based TG inhibitors. These
peptides are typically derived from TG substrates or binding partners and consequently, have
the potential to very precisely modulate the activity of these enzymes. For example, Kim and
colleagues, noting that uteroglobin and lipocortin-1 contain common sequences that antagonize
the interaction of TG 2 and phospholipase A2, synthesized variants of these sequences that
prevented both the polyamination of phospholipase A2 and experimentally induced allergic
conjunctivitis [186]. Similarly, a calmodulin-derived peptide that blocks the interaction of
calmodulin with expanded poly Q attenuated the action of TG on mutant htt [124,125] and had
therapeutic benefit in a transgenic murine HD model [MUMA N ET AL., UNPUBLISHED DATA].
While the aforementioned peptides presumably act in a competitive manner to inhibit TG
activity, other peptides that act irreversibly have been generated using diazo-oxonorleucine
(DON) in place of Q residues. The diazo moiety of DON reacts irreversibly with the TG 2
active site catalytic cysteine residue. Khosla and coworkers synthesized Ac-P(DON)LPF-
NH2, based on a common sequence in gluten proteins (PQLPY) that is acted upon by TG 2,
and employed it to investigate the conformation states of TG 2 [32]. This pentapeptide inhibits
TG 2 with a Ki of 60 nM and k1 of 0.5 min−1, but as of yet, has not been tested in models of
neurodegeneration. The diazo grouping is moderately reactive and the possibility existed that
DON-containing peptides might be cytotoxic. However, Ratan and coworkers have shown that
a DON-containing peptide [Z-DON-Gln-Ile-Val-OMe] is especially useful in studying the
biological effects of TG inhibition in normal and HD cells in culture and in a Drosophila
melanogaster model of HD. Thus far, the results have only been presented at national meetings
[187,188]; however, a more comprehensive report has been submitted for publication. The
findings may be summarized as follows: TG 2 appears to be a transcriptional regulator, not
only of selected metabolic genes (cytochrome c and Pgc1a), but also of a large number of genes
that are dysregulated in neural cells expressing a mutant form of htt. Inhibition of TG 2 restores
downregulated metabolic genes (cytochrome c and Pgc1a) in mutant htt-expressing cells, and
derepression of this pathway increases downstream indicators of metabolic function, increases
survival in a cellular model of HD and decreases the incidence of defective ommatidia in a fly
model of HD [188]. Dysregulation of metabolism in HD is well documented. For example,
Gines et al. demonstrated a deficit in cAMP in HD-knockin mice and in striatal cell models of
HD [189]. The findings suggested that the reduction of cAMP leads to a mitochondrial energy
deficit [189]. Whether TGs cause a change in cAMP-responsive element-mediated gene
transcription of proteins generally involved in metabolic regulation in HD remains to be
determined.
While the work from Ratan's group is preliminary, it does strongly implicate a role for TGs in
the progression of HD. The next stage is to determine other possible promoters with which TG
2 may interact and identify transcriptional proteins that are possibly covalently modified by
TGs. If Z-DON-Gln-Ile-Val-OMe (or analogues) is to prove useful in rodent models of
neurodegenerative diseases, further work is needed to determine whether the compound passes
the BBB and inhibits endogenous brain TGs.
Yuan et al. have demonsrated that small molecule TG 2 inhibitors, such as the reversible
inhibitor monodansylcadaverine and the irreversible dihydroisoxazole inhibitors, KCA075 or
KCC009, promote apoptosis in glioma cells and sensitize the tumors to the chemotherapeutic
agent N,N′-bis(2-chloroethyl)-N-nitrosourea [190,191]. It was suggested that TG2 is a
potential target to enhance cell death and chemosensitivity in glioblastomas [190,191]. The
TG inhibitors developed by Yuan et al. [190,191] might also be useful for investigating the
role of TGs in neurodegenerative diseases.
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■ Elevation of intracellular Ca2+ (Ca2+i) is a consistent feature of Alzheimer's disease
and Huntington's disease.
■ One important consequence of this increase of Ca2+i is likely to be the activation of
transglutaminases (TGs), which, increasing evidence suggests, contributes to
neurodegenerative processes.
■ The mechanisms by which TG-modified products induce cytotoxicity in neural
tissues have not been clearly identified, but studies investigating the toxicity of soluble
and insoluble TG-generated crosslinked aggregates suggest some very interesting
possibilities.
■ One intriguing possibility is that changes in the ratio of γ-glutamylpolyamine/bis-γ-
glutamylpolyamine to γ-glutamyl-ε-lysine linkages may determine the solubility, and
by extension, the toxicity of TG-catalyzed aggregates. Other possibilities include
alteration of transcription factor machinery.
■ Recent studies with rationally designed TG inhibitors and with inhibitors uncovered
by high-throughput screening show that these compounds have beneficial effects in
animal/cellular models of polyglutamine-expansion neurodegenerative diseases. TG
inhibitors have also been shown to be effective in mice harboring glioblastomas.
■ It is predicted that this promising start with TG inhibitors will be extended to animal
models of more common neurodegenerative diseases and will eventually lead to clinical
trials in humans with devastating neurological diseases.
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Figure 1. Closed state of TG 2
The secondary structure of the closed form of TG 2 (PDB 1KV3) is rendered as a ribbon inside
the molecular surface of the protein with an associated GDP depicted in a ball-and-stick
configuration.
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Figure 2. Active state of TG 2 with exposed active site
The secondary structure of the unfolded active form of TG 2 (PDB 2Q3Z) is rendered as a
ribbon inside the molecular surface of the protein.
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Figure 3. Calcium-binding site 1 in TG 3
The coordinating residues for the calcium bound to site 1 of TG 3 (PDB 1L9N) are rendered
as a ribbon, and residues Ala221, Asn224, Asn226 and Asp228 are shown in a ball-and-stick
configuration around the calcium. The molecular surface of the protein is shown in yellow. It
should be noted that the calcium at this site is almost fully enveloped inside the surface of the
protein.
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Figure 4. Calcium-binding site 2 in TG 3
The coordinating residues for the calcium bound to site 2 of TG 3 in both the calcium bound
(PDB 1L9N) and calcium free (PDB 1L9M) are shown. The backbone of the bound state is
rendered in blue and the free state is rendered in green, as are the atoms with the calcium
rendered as in CPK. The residues involved are Asn393, Ser415, Glu443 and Glu448. It should be
noted that there is significant motion of Asn393 and Glu443 upon calcium binding.
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Figure 5. Calcium-binding site 3 in TG 3
The coordinating residues for the calcium bound to site 3 of TG 3 in both the calcium-bound
(PDB 1L9N) and calcium-free state (PDB 1L9M) are shown. The backbone of the bound state
is rendered in blue and the free state is rendered in green, as are the atoms with the calcium
rendered as in CPK. The residues involved are Asp301, Asp303, Asn305, Ser307 and Asp324. Of
note, there is significant motion of Asp324 in this binding site, which in the free state is
significantly displaced from its position in the bound state.
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